ASRT vs HCAT

ASRT's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and inconsistent earnings performance. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given negative earnings and high revenue volatility. Despite strong revenue growth (69.4% YoY) and a low price-to-sales ratio (0.54), the company trades at a significant discount due to deep operational losses and poor capital efficiency. Insider selling activity and a 5-year price decline of 80.4% further undermine confidence. The stock's current valuation appears unsustainable without a clear path to sustained profitability.

HCAT exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic 5-year price decline of 98%. While the stock appears cheap on a Price-to-Book (0.29) and Price-to-Sales (0.24) basis, these are 'value traps' given the negative revenue growth (-6.20%) and a massive collapse in YoY EPS (-3300%). The technical trend is completely bearish (0/100), and insider activity is negative, suggesting a lack of confidence from company leadership.